LOGIN  |  REGISTER
Viking Therapeutics

Upcoming Events & Presentations

Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

January 17
Last Trade: 24.94 -0.15 -0.60

Highlights from Castle’s DecisionDx-SCC poster will be shared in a special podium presentation during the Late Breakers 2025 session on Tuesday, Jan. 21, from 10:45-11:15 a.m. local time FRIENDSWOOD, Texas / Jan 17, 2025 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share data supporting its dermatologic portfolio of tests for skin cancer,...Read more


Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

January 17
Last Trade: 2.22 0.00 0.00

LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai'i...Read more


Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

January 16
Last Trade: 98.66 0.49 0.50

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure Device post cardiac ablation in both concomitant and sequential...Read more


Soligenix to Present at Upcoming Investor Conferences

January 16
Last Trade: 2.35 0.08 3.52

PRINCETON, N.J., Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming conferences below. Sequire Investor Summit, held January 21 to 23 at Condado...Read more


Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

January 15
Last Trade: 3.71 -0.01 -0.27

BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming Sequire Investor Summit being held January 21-23,...Read more


Alzamend Neuro to Present at the Sequire Investor Summit

January 15
Last Trade: 1.16 0.01 0.87

Company to report on progress with clinical trials to be initiated in 2025 and expected milestones ATLANTA / Jan 15, 2025 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today...Read more


Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

January 14
Last Trade: 12.98 0.29 2.29

CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera...Read more


Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025

January 14
Last Trade: 1.84 0.00 0.00

SAN DIEGO and SUZHOU, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will host a virtual key opinion leader (KOL) event on Saturday, January 25, 2025 at 1:00 PM ET, featuring Aurélien Marabelle, MD, PhD (Université Paris-Saclay), Daneng Li, MD (City of Hope), and Marwan Fakih, MD (City of Hope), who...Read more


Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

January 14
Last Trade: 0.80 0.02 2.37

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) to be highlighted in an oral presentation GAINESVILLE, Fla. / Jan 14, 2025 / Business Wire / Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living...Read more


Regeneron Pharmaceuticals Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 681.58 -11.65 -1.68

Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD pre-filled syringe (PFS) submission completed; launch...Read more


Veeva Systems to Present at Upcoming Investor Conference

January 13
Last Trade: 216.59 1.84 0.86

PLEASANTON, Calif., Jan. 13, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conference: 27th Annual Needham Growth Conference. Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy, will present on Thursday, January 16, 2025, at 1:30 p.m. Eastern Time. The above presentation will be webcast. Link to the live and archived webcast will be available on Veeva's...Read more


Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 71.93 -0.54 -0.75

2025 will be a transformational year for Incyte with multiple significant milestones, including four potential launches, four pivotal trial readouts, seven proof of concept data readouts and at least three Phase 3 study initiations Well-positioned for long-term growth, the Company has the potential to deliver more than 10 high impact launches across its portfolio by 2030 WILMINGTON, Del. / Jan 13, 2025 / Business Wire / Incyte...Read more


Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 34.06 0.30 0.89

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion Updates 2025 expected ending cash balance to approximately $6.0 billion Anticipates milestones across 10 prioritized...Read more


Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

January 13
Last Trade: 163.50 -2.30 -1.39

WILMINGTON, Mass. / Jan 13, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, at 2:15 p.m. PT (5:15 p.m. ET). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link...Read more


Telix Pharmaceuticals Presentation to the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 16.78 0.78 4.88

MELBOURNE, Australia and INDIANAPOLIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting this week at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.A.).  The presentation will take place this Wednesday, 15 January at 2:15 pm PST (5:15 pm...Read more


Apellis Pharmaceuticals Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 29.94 0.20 0.67

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024 $98 million in EMPAVELI® U.S. net product revenues, including $23 million in 4Q 2024 Expects submission of EMPAVELI sNDA for C3G and primary IC-MPGN in early 2025; U.S. launch anticipated in 2H 2025, if approved Plans initiation of Phase 3 studies of...Read more


Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

January 13
Last Trade: 17.61 -0.03 -0.17

Nanosecond PFA 360° Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission MIAMI / Jan 13, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its nsPFA technology will be featured in a late-breaking science session and a live case...Read more


Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 1.11 0.00 0.00

PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease  Company completed BLA submission for PRGN-2012 for treatment of adults with RRP  Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash runway well into 2026, beyond the anticipated launch in...Read more


Chimerix to Speak Today at The White House Cancer Moonshot Forum

January 13
Last Trade: 3.55 -0.11 -3.01

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, announced today that Dr. Joshua E. Allen, Chief Scientific Officer at Chimerix, will speak at the Biden Cancer Moonshot Mission Report 2024 – And Beyond. Dr. Allen’s remarks will cover the program’s impact on...Read more


Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 3.37 0.04 1.20

Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, if Approved, Should Play an Important Role in Efforts to Reduce the Continuing High Disease Burden of HCV BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:...Read more


Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 3.33 -0.10 -2.92

Extending Company's leadership position in autoimmune CAR T with prioritized indication strategy; pivoting to late-stage development and commercialization First-to-market opportunity with KYV-101 in stiff person syndrome; 40% enrolled in pivotal Phase 2 trial with first BLA filing targeted for 2026; fast-follow indications in myasthenia gravis and lupus nephritis Efficiently expanding into broader autoimmune indications and increasing...Read more


CAMP4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 4.62 0.17 3.82

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference taking place...Read more


P3 Health Partners to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 13
Last Trade: 0.21 -0.01 -4.81

HENDERSON, Nev. / Jan 13, 2025 / Business Wire / P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California. Management will give a presentation on Tuesday, January 14, 2024, at 7:30 AM Pacific Time. A webcast of the presentation will be available...Read more


NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

January 13
Last Trade: 1.19 -0.01 -0.83

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference. Event Information: Event NanoViricides Presentation at the...Read more


Calidi Biotherapeutics Announces Presentation of New Data of Systemic Virotherapy RTNova Platform at the AACR Annual Meeting in April 2025

January 13
Last Trade: 0.89 -0.0015 -0.17

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual...Read more


TC Biopharm to Present at Sequire Investor Summit 2025

January 13
Last Trade: 0.38 -0.01 -3.61

EDINBURGH, Scotland, Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will be presenting a corporate overview at the upcoming Sequire Investor Summit 2025. The conference is scheduled for January...Read more


Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

January 12
Last Trade: 118.39 -1.14 -0.95

WALTHAM, Mass. / Jan 12, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference...Read more


Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

January 12
Last Trade: 128.13 -3.49 -2.65

Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P. Morgan Healthcare Conference. “Ascendis is well-positioned for rapid...Read more


IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

January 12
Last Trade: 22.18 -0.54 -2.38

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates. 43rd Annual J.P. Morgan Healthcare ConferenceMonday, January 13th, 2025, at 5:15 PM PT (8:15 PM...Read more


Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference

January 12
Last Trade: 7.08 0.11 1.58

Increased investment in ZURZUVAE to help accelerate market growth in postpartum depression with the goal of topline revenue growth in 2025 R&D and G&A expenses expected to decrease substantially in 2025 Company anticipates extended cash runway to mid-2027 CAMBRIDGE, Mass. / Jan 12, 2025 / Business Wire / Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s...Read more


Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

January 12
Last Trade: 5.56 -0.25 -4.30

Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025 Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano Med Orano Med partnership on Radio-DARPins now expanded to 10 programs MP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in...Read more


Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

January 12
Last Trade: 0.24 0.0018 0.74

Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy Endpoints in Phase 2 CLOVER-WaM Study for Relapsed/Refractory Waldenstrom’s Macroglobulinemia Plans to Advance Iopofosine I 131 Internally, Through Strategic Partnerships and Other Approaches; Finalizing Confirmatory Study and Pathway for US FDA Accelerated Approval and EMA Prime Marketing...Read more


Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

January 10
Last Trade: 72.51 -0.24 -0.33

ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million 2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024 NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S....Read more


Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

January 10
Last Trade: 29.02 -0.08 -0.27

 Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C...Read more


Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 10
Last Trade: 3.43 0.27 8.54

SEATTLE, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 43nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 15, 2025, at 3:45 p.m. PT....Read more


Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

January 10
Last Trade: 1.24 -0.01 -0.80

NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be...Read more


MAIA Biotechnology to Present at Biotech Showcase 2025

January 10
Last Trade: 2.00 -0.02 -0.94

CEO to detail THIO-101 expansion trial and upcoming trials in multiple indications CHICAGO / Jan 10, 2025 / Business Wire / MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chief Executive Officer Vlad Vitoc, M.D. will present at the Biotech Showcase™ 2025 investor conference taking place in San...Read more


BullFrog AI to Present at Biotech Showcase and RESI JPM During JP Morgan Week

January 10
Last Trade: 2.12 0.01 0.47

GAITHERSBURG, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced its participation in the TechBio track at Biotech Showcase and RESI JPM, both taking place during the annual JP...Read more


AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 171.56 -7.64 -4.26

NORTH CHICAGO, Ill., Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that...Read more


Masimo to Present in the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 172.29 2.35 1.38

IRVINE, Calif. / Jan 09, 2025 / Business Wire / Masimo (NASDAQ: MASI) today announced that its management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a...Read more


Chemed Corporation to Present at the 43rd Annual JPMorgan Healthcare Conference

January 9
Last Trade: 554.73 1.84 0.33

CINCINNATI / Jan 09, 2025 / Business Wire / Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 43rd Annual JPMorgan Healthcare Conference on Tuesday, January 14, 2024, at approximately 10:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA. The presentation will be webcast live and can be accessed through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be...Read more


Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 42.57 0.43 1.02

FORT WORTH, Texas / Jan 09, 2025 / Business Wire / Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 1:30 p.m. PT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since...Read more


Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 14.13 -0.64 -4.33

WALTHAM, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that John Cox, president and chief executive officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15,...Read more


Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 13.34 -0.25 -1.84

CAMBRIDGE, England & BOSTON / Jan 09, 2025 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate at the 43rd Annual J.P. Morgan Healthcare Conference in a podium presentation on Tuesday, Jan. 14, at 5:15 p.m. PT, followed by a...Read more


Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.

January 9
Last Trade: 2.21 -0.05 -2.21

Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease  ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will be led by LeAnne Bloedon, VP, Head of...Read more


Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 1.11 0.00 0.00

GERMANTOWN, Md., Jan. 9, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 AM PT in San Francisco, California. Participants may...Read more


Lyell Immunopharma to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

January 9
Last Trade: 0.58 0.02 3.06

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate a pivotal trial in the 2nd line by early 2026 Presenting additional data from the ongoing Phase 1-2 trial in 3rd line+ setting and initial clinical data in 2nd line setting in mid-2025 Discontinuing development of LYL119, a ROR1-targeting CAR T-cell product candidate for solid tumors, to...Read more


RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9
Last Trade: 1.20 0.01 0.84

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan...Read more


Amgen To Present At 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 272.11 2.68 0.99

THOUSAND OAKS, Calif., Jan. 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Monday, January 13, 2025. Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The...Read more


Bio-Techne To Present At Phacilitate Advanced Therapies Week 2025

January 8
Last Trade: 75.83 -0.27 -0.35

MINNEAPOLIS, Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and solutions supporting cell and gene therapy development and manufacturing at Phacilitate's Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison Convention Center in Dallas, Texas. Bio-Techne will feature its cell and...Read more


Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 31.43 -0.85 -2.63

CARLSBAD, Calif., Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Wednesday, January 15, 2025. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A...Read more


RadNet to Present at the 43rd Annual J.P. Morgan Healthcare Conference January 15th, 2025

January 8
Last Trade: 59.86 -1.02 -1.68

LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer and Dr. Gregory Sorensen, Executive Vice President and...Read more


CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 40.53 0.23 0.57

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be...Read more


Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

January 8
Last Trade: 59.07 2.72 4.83

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET (7:30 a.m. PT) on Wednesday, January 15, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel...Read more


Ocular Therapeutix to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

January 8
Last Trade: 8.01 -0.04 -0.50

Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real...Read more


Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 12.39 -0.13 -1.04

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at...Read more


Liquidia to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 12.89 0.38 3.04

MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on...Read more


Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 8.03 -0.10 -1.23

WALTHAM, Mass. and BOULDER, Colo., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 7:30 a.m. PT/10:30 a.m. ET. A live...Read more


Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 3.16 -0.09 -2.77

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive...Read more


Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

January 8
Last Trade: 9.88 -0.09 -0.90

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. The audio link for Emergent's session may be...Read more


Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 6.14 0.04 0.66

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the...Read more


Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 9.36 -0.10 -1.06

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT). A live audio webcast of the presentation will be available on the Investors &...Read more


Definitive Healthcare to Present at the 27th Annual Needham Growth Conference

January 8
Last Trade: 3.94 -0.01 -0.25

FRAMINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Kevin Coop, and its Chief Financial Officer, Rick Booth, will present at the 27th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 15, 2025, at 2:15...Read more


Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 4.43 -0.07 -1.56

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT. A live webcast...Read more


Rigel Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 20.13 2.78 16.02

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. To access...Read more


iTeos Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 8.01 0.27 3.49

WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San...Read more


Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 3.37 0.04 1.20

BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January...Read more


C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 3.94 0.08 2.07

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST). The presentation will be webcast...Read more


Coherus BioSciences Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 1.39 -0.03 -2.11

REDWOOD CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus...Read more


Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 4.55 -0.08 -1.73

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 7:30 am PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events...Read more


Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

January 8
Last Trade: 12.00 -1.12 -8.54

NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom (“Western study”) of CRB-701 (SYS6002) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco,...Read more


Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 3.27 0.02 0.62

CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT (6:45 p.m. ET). A live webcast of the presentation...Read more


Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 2.61 -0.16 -5.78

EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco. A live...Read more


CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 0.84 -0.0071 -0.84

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT. A live webcast of the presentation will be available on the Events and...Read more


Outset Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8
Last Trade: 0.79 -0.03 -3.45

SAN JOSE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that Chair & CEO Leslie Trigg will present at the 43rd annual J.P. Morgan Healthcare conference on Wednesday, January 15, 2025, at 8:15 a.m. Pacific time. A live and archived webcast of the presentation...Read more


Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 11.30 -0.04 -0.35

PITTSBURGH, Jan. 7, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025. The company's presentation and fireside chat will begin at 8:15 a.m. PT / 11:15 a.m. ET. A live webcast of the event can be found at investor.viatris.com. An archived version of the...Read more


Repligen to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 160.51 -2.34 -1.44

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live...Read more


Teleflex to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 181.27 -0.18 -0.10

WAYNE, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT). A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor...Read more


Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 37.59 1.74 4.85

NEW HAVEN, Conn., Jan. 7, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 13, 2025, at 8:15 am (PT). About Biohaven  Biohaven is a biopharmaceutical company focused on the...Read more


Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 12.98 0.29 2.29

CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern...Read more


Xenon Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 38.52 -1.10 -2.78

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025. Company...Read more


Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

January 7
Last Trade: 40.61 0.32 0.79

WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025, at 9:00 a.m. PT/12:00 p.m....Read more


Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 25.14 1.13 4.71

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 11:15 a.m. P.T. A live webcast of the Company...Read more


BioCryst Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 7.45 0.39 5.52

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About...Read more


Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 13.08 0.08 0.62

WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT/ 1:30 p.m. ET. A live webcast of the fireside chat can be accessed...Read more


Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 4.46 0.14 3.24

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m....Read more


Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 10.04 -0.07 -0.69

DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus...Read more


Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 1.85 -0.01 -0.54

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Management will...Read more


AnaptysBio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 15.85 0.82 5.46

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET. A live webcast of the presentation will be available on the...Read more


Annexon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7
Last Trade: 4.20 0.09 2.19

BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the 43ʳᵈ Annual J.P. Morgan Healthcare Conference on...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE